30566-92-8

Usage

Uses

Used in Pharmaceutical Industry:
5-(N,N-Dibenzylglycyl)salicylamide is used as an intermediate in the synthesis of labetalol, a medication used for the treatment of high blood pressure. Its role in the production process is crucial, as it helps in the formation of the final drug product.
As an intermediate compound, 5-(N,N-Dibenzylglycyl)salicylamide plays a significant role in the development and manufacturing of labetalol, which is an essential drug for managing hypertension. Its chemical properties and structure make it a valuable component in the pharmaceutical industry, contributing to the creation of effective medications for various health conditions.

InChI:InChI=1/C23H22N2O3/c24-23(28)20-13-19(11-12-21(20)26)22(27)16-25(14-17-7-3-1-4-8-17)15-18-9-5-2-6-10-18/h1-13,26H,14-16H2,(H2,24,28)/p+1

Upstream product

• 73866-23-6 5-(2-bromoacetyl)-2-hydroxybenzamide 
• 103-49-1 dibenzylamine 
• 30914-88-6 2,2-dimethyl-4-keto-1,3-benzoxazine 
• 65-45-2 salicylamide 
• 6629-80-7 2-Phenyl-2,3-dihydro-benzo[e][1,3]oxazin-4-one 
• 33254-88-5 5-chloroacetylsalicylamide 

Downstream Products

• 54645-51-1 2-Butyloxy-5-(N,N-dibenzylglycyl)benzamide 
• 54645-50-0 5-(N,N-Dibenzylglycyl)-2-(pentyloxy)benzamide 
• 54645-52-2 5-(N,N-dibenzylglycyl)-2-hexyloxybenzamide 
• 54645-77-1 5-(N,N-dibenzylglycyl)-2-(3-hydroxypropoxy)benzamide 
• 54645-55-5 5-(N,N-dibenzylglycyl)-2-(2-hydroxyethoxy)benzamide 
• 81579-56-8 5-{2-[2-(3,4-Dihydro-2H-quinolin-1-yl)-1-methyl-ethylamino]-1-hydroxy-ethyl}-2-hydroxy-benzamide 
• 32780-78-2 5-[1-hydroxy-2-(1-methyl-3,3-diphenylpropyl)aminoethyl]salicylamide 
• 81580-07-6 2-Hydroxy-5-[1-hydroxy-2-(1-methyl-3-p-tolyl-propylamino)-ethyl]-benzamide 
• 81580-13-4 5-{2-[3-(4-Dimethylamino-phenyl)-1-methyl-propylamino]-1-hydroxy-ethyl}-2-hydroxy-benzamide 
• 81580-10-1 5-{2-[3-(3,4-Dimethoxy-phenyl)-1-methyl-propylamino]-1-hydroxy-ethyl}-2-hydroxy-benzamide 
• 81580-08-7 2-Hydroxy-5-{1-hydroxy-2-[1-methyl-3-(4-trifluoromethyl-phenyl)-propylamino]-ethyl}-benzamide 
• 81580-16-7 5-{2-[1-Ethyl-3-(4-fluoro-phenyl)-propylamino]-1-hydroxy-ethyl}-2-hydroxy-benzamide 
• 72371-11-0 5-(2-[3-(N-methylanilino)-2-propylamino]-1-hydroxyethyl)-salicylamide 
• 81580-04-3 5-{2-[2-(Ethyl-phenyl-amino)-1-methyl-ethylamino]-1-hydroxy-ethyl}-2-hydroxy-benzamide 

Relevant academic research and scientific papers

Synthetic method of 5-N,N-dibenzylamine acetyl salicylamide

The invention discloses a synthetic method of 5-N,N-dibenzylamine acetyl salicylamide. The synthetic method comprises the steps of protecting salicylamide with aldehyde, ketone or acetal and ketal with different substituents, reacting with an alpha-halogenated acylation reagent so as to obtain an intermediate II, substituting halogen atoms with dibenzylamine, and finally carrying out acidificationdeprotection, so as to obtain 5-N,N-dibenzylamine acetyl salicylamide. The synthetic method provided by the invention has the characteristics of high yield, few impurities, low cost, easiness in amplification and the like.

A 5 - (N, N - dibenzyl amino) acetyl salicylic amide preparation method

The invention relates to a preparation method for 5-(N, N-dibenzylamino)acetylsalicylamide. The method includes: adding salicylamide and chloroacetyl chloride into a container to carry out reaction according to a mole ratio of 1: 2.5-5.5, using an ionic liquid as the solvent, with the mole ratio of the ionic liquid to salicylamide being 5-10:1, carrying out reaction at 35-55DEG C under atmospheric pressure, then at the end of the reaction, taking an organic solvent to perform extraction to obtain 5-chloracetylsalicylamide, adding the prepared 5-chloracetylsalicylamide and dibenzylamine into a mixed solution of water and methanol, with the volume ratio of methanol to water being 2-4:1, carrying out heating reaction at 50-70DEG C for 2-4h, with 5-chloracetylsalicylamide and dibenzylamine being in a mole ratio of 1:1.0-1.2, at the end of the reaction, conducting vacuum distillation to remove the solvent, and performing recrystallization to obtain 5-(N, N-dibenzylamino)acetylsalicylamide. The preparation method provided by the invention has the characteristics of low production cost, short synthesis step, high yield, and small environmental pollution.

PHENETHANOLAMINE ETHERS

Compounds of the general formula I and physiologically acceptable acid addition salts thereof:-STR1 in which R 1 is a lower alkyl, lower alkenyl, or arylalkyl radical, which radicals may optionally be substituted by one or more alkoxy or hydroxy groups. R. sup.2 represents a hydrogen atom or a lower alkyl radical which may optionally be substituted by one or more hydroxy groups, amino groups, or heterocyclic rings containing one or more heteroatoms, or R 2 represents a cycloalkyl, arylalkyl or aryloxyalkyl radical, which radicals may optionally be substituted by one or more alkoxy or hydroxy groups;R 3 represents a hydrogen atom or a benzyl group; X represents a group of formula--CONR. sup.4 R. sup.5 where R 4 and R 5 may be the same or different and each represents hydrogen or a lower alkyl group;WITH THE PROVISO THAT WHEN R 2 is tertiary butyl and R 1 is a benzyl group, R 3 represents a hydrogen atom. The compounds have a blocking action on β-adrenergic receptors and in some cases an antagonising effect on α-adrenergic receptors.